Aliases & Classifications for Fainting

MalaCards integrated aliases for Fainting:

Name: Fainting 54 43

Summaries for Fainting

NINDS : 54 Syncope is a medical term used to describe a temporary loss of consciousness due to the sudden decline of blood flow to the brain. Syncope is commonly called fainting or “passing out.” If an individual is about to faint, he or she will feel dizzy, lightheaded, or nauseous and their field of vision may “white out” or “black out.”  The skin may be cold and clammy.  The person drops to the floor as he or she loses consciousness.  After fainting, an individual may be unconscious for a minute or two, but will revive and slowly return to normal.  Syncope can occur in otherwise healthy people and affects all age groups, but occurs more often in the elderly.  There are several types of syncope.  Vasovagal syncope usually has an easily identified triggering event such as emotional stress, trauma, pain, the sight of blood, or prolonged standing.  Carotid sinus syncope happens because of constriction of the carotid artery in the neck and can occur after turning the head, while shaving, or when wearing a tight collar.  Situational syncope happens during urination, defecation, coughing, or as a result of gastrointestinal stimulation.  Syncope can also be a symptom of heart disease or abnormalities that create an uneven heart rate or rhythm that temporarily affect blood volume and its distribution in the body.  Syncope isn’t normally a primary sign of a neurological disorder, but it may indicate an increased risk for neurologic disorders such as Parkinson’s disease, postural orthostatic tachycardia syndrome (POTS), diabetic neuropathy, and other types of neuropathy.  Certain classes of drugs are associated with an increased risk of syncope, including diuretics, calcium antagonists, ACE inhibitors, nitrates, antipsychotics, antihistamines, levodopa, narcotics, and alcohol.

MalaCards based summary : Fainting is related to atrial fibrillation and myocardial infarction. An important gene associated with Fainting is KCNH2 (Potassium Voltage-Gated Channel Subfamily H Member 2), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Ranolazine and Timolol have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and skin.

MedlinePlus : 43 Fainting is a temporary loss of consciousness. If you're about to faint, you'll feel dizzy, lightheaded, or nauseous. Your field of vision may "white out" or "black out." Your skin may be cold and clammy. You lose muscle control at the same time, and may fall down. Fainting usually happens when your blood pressure drops suddenly, causing a decrease in blood flow to your brain. It is more common in older people. Some causes of fainting include Heat or dehydration Emotional distress Standing up too quickly Certain medicines Drop in blood sugar Heart problems When someone faints, make sure that the airway is clear and check for breathing. The person should stay lying down for 10-15 minutes. Most people recover completely. Fainting is usually nothing to worry about, but it can sometimes be a sign of a serious problem. If you faint, it's important to see your health care provider and find out why it happened.

Wikipedia : 76 Syncope, also known as fainting, is a loss of consciousness and muscle strength characterized by a fast... more...

Related Diseases for Fainting

Diseases related to Fainting via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 atrial fibrillation 30.1 KCNH2 VWF
2 myocardial infarction 29.2 CHKB F8 VWF
3 syncope 11.4
4 long qt syndrome 11.1
5 postural orthostatic tachycardia syndrome 11.0
6 jervell and lange-nielsen syndrome 1 11.0
7 chronic orthostatic intolerance 11.0
8 myotonia congenita 10.9
9 myotonia congenita, autosomal recessive 10.9
10 aortic valve disease 2 10.9
11 long qt syndrome 1 10.8
12 brugada syndrome 10.8
13 familial atrial fibrillation 10.8
14 ectopic pregnancy 10.8
15 catecholaminergic polymorphic ventricular tachycardia 10.8
16 osteogenesis imperfecta, type xiii 10.8
17 hypertrophic cardiomyopathy 10.8
18 vibratory urticaria 10.7
19 autoimmune autonomic ganglionopathy 10.7
20 multiple system atrophy 1 10.7
21 syncope, familial vasovagal 10.7
22 patent foramen ovale 10.7
23 familial progressive cardiac conduction defect 10.7
24 pulmonary hypertension, primary, 1 10.7
25 hyperinsulinemic hypoglycemia, familial, 7 10.7
26 brugada syndrome 2 10.7
27 hereditary alpha tryptasemia syndrome 10.7
28 cardiomyopathy, familial hypertrophic, 1 10.7
29 brugada syndrome 3 10.7
30 arrhythmogenic right ventricular cardiomyopathy 10.7
31 atrial fibrillation and stroke 10.7
32 brugada syndrome 4 10.7
33 hypoadrenocorticism, familial 10.7
34 brugada syndrome 5 10.7
35 brugada syndrome 6 10.7
36 peters-plus syndrome 10.7
37 brugada syndrome 7 10.7
38 multiple system atrophy with orthostatic hypotension 10.7
39 brugada syndrome 8 10.7
40 long qt syndrome 2 10.7
41 brugada syndrome 1 10.7
42 long qt syndrome 3 10.7
43 ovarian cyst 10.7
44 brugada syndrome 9 10.7
45 pulmonary hypertension 10.7
46 dilated cardiomyopathy 10.7
47 amyloidosis 10.7
48 cerebritis 10.0
49 compartment syndrome 10.0 CHKB F8
50 ventricular fibrillation, paroxysmal familial, 1 10.0 CHKB KCNH2

Graphical network of the top 20 diseases related to Fainting:



Diseases related to Fainting

Symptoms & Phenotypes for Fainting

Drugs & Therapeutics for Fainting

Drugs for Fainting (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 503)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranolazine Approved, Investigational Phase 4,Phase 2 142387-99-3, 95635-55-5 56959
2
Timolol Approved Phase 4,Phase 2,Not Applicable 26839-75-8 33624 5478
3
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
4
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 185243-69-0
5
Propranolol Approved, Investigational Phase 4,Phase 2,Not Applicable 525-66-6 4946
6
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
7
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
8
Carvedilol Approved, Investigational Phase 4,Phase 1,Phase 2 72956-09-3 2585
9 Titanium dioxide Approved Phase 4 13463-67-7
10
Petrolatum Approved, Investigational Phase 4,Phase 2 8009-03-8
11
Sertraline Approved Phase 4 79617-96-2 68617
12
Amlodipine Approved Phase 4 88150-42-9 2162
13
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
14
Losartan Approved Phase 4 114798-26-4 3961
15
Midodrine Approved Phase 4,Not Applicable 133163-28-7, 42794-76-3 4195
16
Benzoyl peroxide Approved Phase 4,Phase 3 94-36-0 7187
17
Ephedrine Approved Phase 4,Early Phase 1 299-42-3 9294
18
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Not Applicable 58-93-5 3639
19
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
20
Pseudoephedrine Approved Phase 4,Early Phase 1 90-82-4 7028
21
Gliclazide Approved Phase 4,Phase 3 21187-98-4 3475
22
Treprostinil Approved, Investigational Phase 4,Phase 3,Phase 2 81846-19-7 54786 6918140
23
Adapalene Approved Phase 4 106685-40-9 60164
24
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
25
Acitretin Approved Phase 4 55079-83-9 6437841 5284513
26
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
27
Clobetasol Approved, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
28
Bisoprolol Approved Phase 4,Phase 3 66722-44-9 2405
29
Metoprolol Approved, Investigational Phase 4,Phase 3,Not Applicable 37350-58-6, 51384-51-1 4171
30
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
31
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
32
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
33
Clindamycin Approved, Vet_approved Phase 4,Phase 3 18323-44-9 29029
34
Brinzolamide Approved Phase 4 138890-62-7 68844
35
Glyburide Approved Phase 4,Phase 3 10238-21-8 3488
36
Testosterone Approved, Investigational Phase 4 58-22-0 6013
37
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576 3823
38
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
39
Angiotensin II Approved, Investigational Phase 4,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
40
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2 23651-95-8 443940
41
Epoprostenol Approved Phase 4,Phase 3 61849-14-7, 35121-78-9 5280427 5282411
42
Methyltestosterone Approved Phase 4 58-18-4 6010
43
Tavaborole Approved, Investigational Phase 4 174671-46-6
44
Testosterone enanthate Approved Phase 4 315-37-7 9416
45
Atenolol Approved Phase 4 29122-68-7 2249
46
Donepezil Approved Phase 4,Phase 2 120014-06-4 3152
47
Enalaprilat Approved Phase 4 76420-72-9 6917719
48
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
49
Tamsulosin Approved, Investigational Phase 4,Phase 3 106133-20-4 129211
50
Silodosin Approved Phase 4,Phase 3 160970-54-7

Interventional clinical trials:

(show top 50) (show all 524)
# Name Status NCT ID Phase Drugs
1 Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study) Unknown status NCT01621464 Phase 4
2 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
3 Safety of Amiodarone and Ranolazine Together in Patients With Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
4 The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
5 Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas Unknown status NCT01960569 Phase 4 active product ( Thrombexx) assigned to arm 1
6 A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial) Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
7 Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study Unknown status NCT01275339 Phase 4 Tadalafil;Placebo
8 ISSUE3: International Study on Syncope of Uncertain Etiology 3 Completed NCT00359203 Phase 4
9 Clinical Trial for the Prevention of Vasovagal Syncope Completed NCT00118482 Phase 4 fludrocortisone acetate
10 Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
11 ELIAS: Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
12 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
13 Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy Completed NCT00947310 Phase 4
14 Comparision of Blood Pressure Variability Between Amlodipine and Losartan Completed NCT01964079 Phase 4 Amlodipine;Losartan
15 Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) Completed NCT01131182 Phase 4 Sitagliptin phosphate;Comparator: Sulfonylurea;Metformin
16 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
17 Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis. Completed NCT01323673 Phase 4 clobetasol propionate 0.05%;Vehicle / Placebo
18 Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries Completed NCT02132247 Phase 4 Diclofenac hydroxyethylpyrrolidine
19 A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis Completed NCT00852761 Phase 4 Olux-E Foam;Clobex lotion
20 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4 Midodrine HCl;Placebo
21 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
22 A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites Completed NCT01722994 Phase 4
23 Postoperative Pain in Single-visit and Multiple-visit Retreatment Cases Completed NCT03042377 Phase 4 Multiple-Visit-"Calcium Hydroxide";Multiple-Visit-"Corticosteroid Paste";Multiple-Visit-"Antibiotic Paste"
24 Effects of Testosterone on Myocardial Repolarization Completed NCT03126656 Phase 4 Testosterone Undecanoate
25 Optimal Balloon Catheter Placement During Sonohysterography Completed NCT01936116 Phase 4
26 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
27 Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin Completed NCT00373360 Phase 4 treprostinil sodium
28 Circadian Ocular Perfusion Pressure and Ocular Blood Flow Completed NCT00800540 Phase 4 Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension;Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
29 Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) Completed NCT02191137 Phase 4 Riociguat (Adempas, BAY63-2521)
30 Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis Completed NCT00936065 Phase 4 Etanercept;Etanercept + Acitretin;Acitretin
31 Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam Completed NCT00842153 Phase 4 Clobetasol propionate foam;Vehicle foam
32 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
33 Epoprostenol for Injection in Pulmonary Arterial Hypertension Completed NCT01105091 Phase 4 ACT-385781A (Actelion Epoprostenol);Flolan®
34 STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% Completed NCT00703846 Phase 4 Ketoconazole
35 Evaluation of PCLs Using Three EUS-FNA Needles Completed NCT01711294 Phase 4
36 Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) Completed NCT01462565 Phase 4 current marketed FLOLAN (epoprostenol sodium);new thermo stable formulation of epoprostenol sodium
37 A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
38 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
39 DUAC® Early Onset Efficacy Study in Japanese Subjects Completed NCT02557399 Phase 4 Duac® fixed dose combination gel;ADA 0.1% gel;CLDM 1% gel
40 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
41 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
42 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
43 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
44 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
45 Combining Donepezil With Perceptual Learning in Normal and Amblyopic Human The Effect of Donepezil on Perceptual Learning in Adult Amblyopia Recruiting NCT03109314 Phase 4 Donepezil
46 Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) Recruiting NCT03278509 Phase 4 Metoprolol Succinate;Bisoprolol
47 A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD Recruiting NCT03539601 Phase 4 Crisaborole ointment, 2%;Hydrocortisone butyrate cream, 0.1%;Pimecrolimus cream, 1%;Crisaborole Vehicle
48 Syncope: Pacing or Recording in the Later Years Active, not recruiting NCT01423994 Phase 4
49 The Effect of Antihypertensive Medication Timing on Morbidity and Mortality Enrolling by invitation NCT02990663 Phase 4
50 Feasibility Study of the Intensive Systolic Blood Pressure Control Enrolling by invitation NCT02817503 Phase 4 Standard BP control;Moderate BP control;Intensive BP control

Search NIH Clinical Center for Fainting

Genetic Tests for Fainting

Anatomical Context for Fainting

MalaCards organs/tissues related to Fainting:

41
Heart, Brain, Skin, Testes, Breast, Thyroid, Bone

Publications for Fainting

Articles related to Fainting:

(show top 50) (show all 207)
# Title Authors Year
1
Putting the Spirit into Culturally Responsive Public Health: Explaining Mass Fainting in Cambodia. ( 29956053 )
2018
2
Case report: fainting during acupuncture stimulation at acupuncture point LI4. ( 28274225 )
2017
3
Fainting Fanconi syndrome clarified by proxy: a case report. ( 28693455 )
2017
4
Sympathetic and parasympathetic cardiac responses to phobia-relevant and disgust-specific emotion provocation in blood-injection-injury phobia with and without fainting history. ( 28667690 )
2017
5
Fainting episode in a pacemaker dependent patient with two implanted devices. Too much of a good thing! ( 28476432 )
2017
6
Comparison of Specific Fainting Characteristics Between Youth With Tilt-Induced Psychogenic Nonsyncopal Collapse Versus Reflex Syncope. ( 28236458 )
2017
7
Mass fainting in garment factories in Cambodia. ( 28398195 )
2017
8
Fainting: What You Should Know. ( 28290650 )
2017
9
Clinical Pearls - how my patients taught me: The fainting lark symptom. ( 27822381 )
2016
10
An Experimental Model of Vasovagal Syncope Induces Cerebral Hypoperfusion and Fainting-Like Behavior in Awake Rats. ( 27658057 )
2016
11
Syncope: Not for the faint hearted. ( 27189260 )
2016
12
Syncope (Fainting). ( 27142609 )
2016
13
Fainting Starting Parenteral Nutrition. ( 25853719 )
2015
14
Fifteen-minute consultation on limiting investigations in the fainting child. ( 26201347 )
2015
15
Prognosis of glioblastoma with faint MGMT methylation-specific PCR product. ( 25575938 )
2015
16
Fainting After Chest Pain. ( 27122877 )
2015
17
Alteration in cardiovascular and postural control relationship in non-fainting elderly individuals. ( 25570750 )
2014
18
Purinergic profile of fainting divers is different from patients with vasovagal syncope. ( 24798778 )
2014
19
Fainting as an unusual presentation of a large inferior vena cava leiomyosarcoma. ( 24837084 )
2014
20
Role of sympathetic nerve activity in the process of fainting. ( 25309444 )
2014
21
Fainting (vasovagal syncope): case reports. ( 25198333 )
2014
22
A mobile system for real-time context-aware monitoring of patients' health and fainting. ( 25946886 )
2014
23
Giving blood donors something to drink before donation can prevent fainting symptoms: is there a physiological or psychological reason? ( 25130724 )
2014
24
57-year-old man with flushing and fainting. ( 23639502 )
2013
25
Small left atrial volume is an independent predictor for fainting during head-up tilt test: the impact of intracardiac volume reserve in vasovagal syncope. ( 22000265 )
2013
26
Long-Term Stability of Uveitis with Faint Anterior Chamber Flare Treated with Once-Daily Topical Ophthalmic Betamethasone. ( 24114448 )
2013
27
External pneumatic compression device prevents fainting in standing weight-bearing MRI: a cohort study. ( 23857423 )
2013
28
Malignant cardioinhibitory vasovagal syncope - an uncommon cardiovascular complication of Roux-en-Y gastric bypass surgery: the fainting syndrome! ( 23063207 )
2013
29
Skin infiltration of nodal peripheral t-cell lymphoma-not otherwise specified identified by skin biopsy of faint eruptions. ( 23723524 )
2013
30
A 40-year-old man with recurrent fainting, hypotension, lower limb edema and oliguria with body weight gain and secondary erythrocytosis. ( 21948352 )
2012
31
A pacemaker to prevent fainting. If your heart rate slows, a device can stop you from dropping. ( 23101130 )
2012
32
What's at the heart of fainting? Most fainting is not related to abnormal heart rhythms. ( 22872881 )
2012
33
Does disgust increase parasympathetic activation in individuals with a history of fainting? A psychophysiological analysis of disgust stimuli with and without blood-injection-injury association. ( 23023164 )
2012
34
The relation between disgust-sensitivity, blood-injection-injury fears and vasovagal symptoms in blood donors: disgust sensitivity cannot explain fainting or blood donation-related symptoms. ( 21906532 )
2012
35
Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor. ( 22699518 )
2012
36
Fainting attacks in children. ( 21695380 )
2012
37
Case 2: 'I feel faint': An adolescent with recurrent dizziness and syncope. ( 23730166 )
2012
38
Fainting, swooning, and syncope. ( 22132356 )
2011
39
Factors associated with fainting: before, during and after whole blood donation. ( 21535440 )
2011
40
Physiologic strategies to prevent fainting responses during or after whole blood donation. ( 21645008 )
2011
41
Episode of fainting and tetany after an evaluation technique of the upper cervical region: a case report. ( 20724209 )
2011
42
To avoid fainting: cross the legs and not the fingers. ( 20106794 )
2010
43
A 46-year-old woman with chin pain and a fainting spell. ( 20391493 )
2010
44
Correlations between urinary excretion of catecholamines and electrocardiographic parameters of vagal hyperreactivity in infants with fainting spells. Implication of sympathetic hypotonia? ( 21074121 )
2010
45
A 37-year-old man with recurrent fainting: a short communication. ( 20348158 )
2010
46
Fainting with HIV. ( 20800149 )
2010
47
Clinical reasoning: a teenage girl with excessive daytime sleepiness, "fainting spells," and dream mentations. ( 20498429 )
2010
48
Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity. ( 20111911 )
2010
49
Persistent fainting after implantation of a "curative" pacemaker. ( 19118314 )
2009
50
Increased phase synchronization and decreased cerebral autoregulation during fainting in the young. ( 19820196 )
2009

Variations for Fainting

Expression for Fainting

Search GEO for disease gene expression data for Fainting.

Pathways for Fainting

GO Terms for Fainting

Cellular components related to Fainting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.62 F8 VWF

Biological processes related to Fainting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.32 F8 VWF
2 platelet degranulation GO:0002576 9.26 F8 VWF
3 platelet activation GO:0030168 9.16 F8 VWF
4 hemostasis GO:0007599 8.96 F8 VWF
5 blood coagulation, intrinsic pathway GO:0007597 8.62 F8 VWF

Sources for Fainting

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....